As of close of business last night, Legend Biotech Corp ADR’s stock clocked out at $54.80, down -0.24% from its previous closing price of $54.93. In other words, the price has decreased by -$0.13 from its previous closing price. On the day, 1662254 shares were traded. LEGN stock price reached its highest trading level at $55.91 during the session, while it also had its lowest trading level at $54.20.
Ratios:
To gain a deeper understanding of LEGN’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.83 and its Current Ratio is at 6.92. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.26.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on April 03, 2024, initiated with a Overweight rating and assigned the stock a target price of $82.
On March 13, 2024, Raymond James started tracking the stock assigning a Outperform rating and target price of $86.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LEGN now has a Market Capitalization of 9.97B and an Enterprise Value of 8.99B. For the stock, the TTM Price-to-Sale (P/S) ratio is 34.96 while its Price-to-Book (P/B) ratio in mrq is 7.97. Its current Enterprise Value per Revenue stands at 31.52 whereas that against EBITDA is -18.81.
Stock Price History:
Over the past 52 weeks, LEGN has reached a high of $77.32, while it has fallen to a 52-week low of $48.20. The 50-Day Moving Average of the stock is 60.37, while the 200-Day Moving Average is calculated to be 64.42.
Shares Statistics:
It appears that LEGN traded 965.49K shares on average per day over the past three months and 844.08k shares per day over the past ten days. A total of 181.91M shares are outstanding, with a floating share count of 180.13M. Insiders hold about 0.98% of the company’s shares, while institutions hold 46.96% stake in the company. Shares short for LEGN as of Mar 15, 2024 were 10.51M with a Short Ratio of 10.89, compared to 9.94M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 5.78% and a Short% of Float of 11.12%.
Earnings Estimates
As of right now, 4 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.34 for the current quarter, with a high estimate of -$0.08 and a low estimate of -$0.75, while EPS last year was -$0.68. The consensus estimate for the next quarter is -$0.56, with high estimates of -$0.09 and low estimates of -$0.77.
Analysts are recommending an EPS of between -$0.5 and -$2.73 for the fiscal current year, implying an average EPS of -$1.51. EPS for the following year is -$0.63, with 9 analysts recommending between $0.42 and -$1.71.
Revenue Estimates
In the current quarter, 10 analysts expect revenue to total $164.15M. It ranges from a high estimate of $202.5M to a low estimate of $80M. As of the current estimate, Legend Biotech Corp ADR’s year-ago sales were $36.34M, an estimated increase of 351.80% from the year-ago figure. For the next quarter, 10 analysts are estimating revenue of $141.81M, an increase of 93.40% less than the figure of $351.80% in the same quarter last year. There is a high estimate of $209.8M for the next quarter, whereas the lowest estimate is $85M.
A total of 16 analysts have provided revenue estimates for LEGN’s current fiscal year. The highest revenue estimate was $701.9M, while the lowest revenue estimate was $450M, resulting in an average revenue estimate of $597.34M. In the same quarter a year ago, actual revenue was $285.14M, up 109.50% from the average estimate. Based on 15 analysts’ estimates, the company’s revenue will be $1.09B in the next fiscal year. The high estimate is $1.53B and the low estimate is $841.4M. The average revenue growth estimate for next year is up 82.30% from the average revenue estimate for this year.
